ArticleExperimental and therapeutic medicine2021

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.

Vassiliki Mpakou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.